Czechia – Immunosuppressive agents – Imunosupresiva - inhibitory TNF alfa - infliximab II. - i.v. podání
Institut klinické a experimentální medicíny awarded a contract of undisclosed value to Merck Sharp & Dohme s.r.o. for Professional Services & Consulting in June 2024 — one of 690 awards this buyer has made.
Buying agency
Institut klinické a experimentální medicínyWinning supplier
Merck Sharp & Dohme s.r.o.Contract description
Czechia – Immunosuppressive agents – Imunosupresiva - inhibitory TNF alfa - infliximab II. - i.v. podání
Related awards · Institut klinické a experimentální medicíny
690 awardsThe buyer's full award list ranked by value, with the winning supplier, date and sector on every row — plus CSV / API export.
- ocds-ted-274488-2025IMOS Brno, a.s.Kč375M29 Apr 2025 Construction
- ocds-ted-440632-2026Avenier a.s.Kč289M26 Jun 2026 Healthcare
- ocds-ted-746939-2024PROMEDICA PRAHA GROUP, a.s.Kč164M06 Dec 2024 Professional Services
Other wins · Merck Sharp & Dohme s.r.o.
49 winsThe supplier's complete win history across every buyer it sells to — not just the handful shown here.
- ocds-ted-324979-2025Fakultní Thomayerova nemocniceKč647M20 May 2025 Professional Services
- ocds-ted-531271-2025Fakultní nemocnice Hradec KrálovéKč577M13 Aug 2025 Professional Services
- ocds-ted-120271-2025Všeobecná fakultní nemocnice v PrazeKč362M24 Feb 2025 Professional Services
Premium · full dataset
See the full award context.
Competing bids, award margins and every related contract for Institut klinické a experimentální medicíny and Merck Sharp & Dohme s.r.o. — one subscription unlocks everything.
Sign Up Free →Free account · cancel anytime · 14-day money-back